immunate powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii/von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 500iu/375iu
immunate powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii/von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 1000iu/750iu
immunate 1000iu+750iu powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii, von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 1000iu+750iu
immunate 250iu+190iu powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii, von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 250iu+190iu
immunate 500iu+375iu powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii, von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 500iu+375iu
wilate - von willebrand factor/coagulation factor viii complex (human) (von willebrand factor/coagulation factor viii complex- h
octapharma usa inc - antihemophilic factor human (unii: 839moz74gk) (antihemophilic factor human - unii:839moz74gk), von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - antihemophilic factor human 100 [iu] in 1 ml - wilate is indicated in children and adults with von willebrand disease for: - on-demand treatment and control of bleeding episodes - perioperative management of bleeding wilate is indicated in adolescents and adults with hemophilia a for: - routine prophylaxis to reduce the frequency of bleeding episodes - on-demand treatment and control of bleeding episodes wilate is contraindicated in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reactions, to human plasma-derived products, any ingredient in the formulation [see description (11) ] , or components of the container. risk summary there are no data with wilate use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with wilate. wilate was given to four subjects (3 type 3 and 1 type 2b) during labor and delivery in one clinical study. two subjects underwent vaginal delivery (type 3) and two subjects had a cesarean section (type 3/type 2b). in this study all pro
csl singapore biostate human coagulation factor viii 500 iu/von willebrand factor 1000 iu powder for injection vial
csl behring australia pty ltd - factor viii,von willebrand factor -
csl singapore biostate human coagulation factor viii 250iu/von willebrand factor 500 iu powder for injection vial
csl behring australia pty ltd - factor viii,von willebrand factor -
csl malaysia biostate® human coagulation factor viii 500 iu/von willebrand factor 1000 iu powder for injection vial
csl behring australia pty ltd - factor viii,von willebrand factor -
csl malaysia biostate® human coagulation factor viii 250 iu/von willebrand factor 500 iu powder for injection vial
csl behring australia pty ltd - factor viii,von willebrand factor -